1192 related articles for article (PubMed ID: 33215344)
21. A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023.
Cardinale R; Won M; Choucair A; Gillin M; Chakravarti A; Schultz C; Souhami L; Chen A; Pham H; Mehta M
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1422-8. PubMed ID: 16750317
[TBL] [Abstract][Full Text] [Related]
22. Management of single brain metastasis: a practice guideline.
Mintz A; Perry J; Spithoff K; Chambers A; Laperriere N
Curr Oncol; 2007 Aug; 14(4):131-43. PubMed ID: 17710205
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approaches.
Dhermain F
Chin J Cancer; 2014 Jan; 33(1):16-24. PubMed ID: 24384237
[TBL] [Abstract][Full Text] [Related]
24. Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
Cabrera AR; Kirkpatrick JP; Fiveash JB; Shih HA; Koay EJ; Lutz S; Petit J; Chao ST; Brown PD; Vogelbaum M; Reardon DA; Chakravarti A; Wen PY; Chang E
Pract Radiat Oncol; 2016; 6(4):217-225. PubMed ID: 27211230
[TBL] [Abstract][Full Text] [Related]
25. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant glioma.
Tsao MN; Mehta MP; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):47-55. PubMed ID: 16111571
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
[TBL] [Abstract][Full Text] [Related]
27. The role of imaging for the management of newly diagnosed glioblastoma in adults: a systematic review and evidence-based clinical practice guideline update.
Lundy P; Domino J; Ryken T; Fouke S; McCracken DJ; Ormond DR; Olson JJ
J Neurooncol; 2020 Nov; 150(2):95-120. PubMed ID: 33215340
[TBL] [Abstract][Full Text] [Related]
28. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme.
Monjazeb AM; Ayala D; Jensen C; Case LD; Bourland JD; Ellis TL; McMullen KP; Chan MD; Tatter SB; Lesser GJ; Shaw EG
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):743-8. PubMed ID: 21236604
[TBL] [Abstract][Full Text] [Related]
29. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer.
Choi NC; Herndon JE; Rosenman J; Carey RW; Chung CT; Bernard S; Leone L; Seagren S; Green M
J Clin Oncol; 1998 Nov; 16(11):3528-36. PubMed ID: 9817271
[TBL] [Abstract][Full Text] [Related]
30. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03.
Tsien C; Moughan J; Michalski JM; Gilbert MR; Purdy J; Simpson J; Kresel JJ; Curran WJ; Diaz A; Mehta MP;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):699-708. PubMed ID: 18723297
[TBL] [Abstract][Full Text] [Related]
31. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
[TBL] [Abstract][Full Text] [Related]
32. Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapy.
Beauchesne P; Bernier V; Carnin C; Taillandier L; Djabri M; Martin L; Michel X; Maire JP; Khalil T; Kerr C; Gorlia T; Stupp R; Pedeux R
Neuro Oncol; 2010 Jun; 12(6):595-602. PubMed ID: 20511183
[TBL] [Abstract][Full Text] [Related]
33. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma.
Hudes RS; Corn BW; Werner-Wasik M; Andrews D; Rosenstock J; Thoron L; Downes B; Curran WJ
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):293-8. PubMed ID: 10030252
[TBL] [Abstract][Full Text] [Related]
34. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review.
Laperriere N; Zuraw L; Cairncross G;
Radiother Oncol; 2002 Sep; 64(3):259-73. PubMed ID: 12242114
[TBL] [Abstract][Full Text] [Related]
35. Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients.
Coughlin C; Scott C; Langer C; Coia L; Curran W; Rubin P
Int J Radiat Oncol Biol Phys; 2000 Dec; 48(5):1351-8. PubMed ID: 11121633
[TBL] [Abstract][Full Text] [Related]
36. Treating Glioblastoma Multiforme (GBM) with super hyperfractionated radiation therapy: Implication of temporal dose fractionation optimization including cancer stem cell dynamics.
Yu VY; Nguyen D; O'Connor D; Ruan D; Kaprealian T; Chin R; Sheng K
PLoS One; 2021; 16(2):e0245676. PubMed ID: 33524046
[TBL] [Abstract][Full Text] [Related]
37. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
Lunsford LD; Flickinger JC; Larson D
Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution.
Hulshof MC; Koot RW; Schimmel EC; Dekker F; Bosch DA; González González D
Strahlenther Onkol; 2001 Jun; 177(6):283-90. PubMed ID: 11446316
[TBL] [Abstract][Full Text] [Related]
39. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline.
Kalkanis SN; Kondziolka D; Gaspar LE; Burri SH; Asher AL; Cobbs CS; Ammirati M; Robinson PD; Andrews DW; Loeffler JS; McDermott M; Mehta MP; Mikkelsen T; Olson JJ; Paleologos NA; Patchell RA; Ryken TC; Linskey ME
J Neurooncol; 2010 Jan; 96(1):33-43. PubMed ID: 19960230
[TBL] [Abstract][Full Text] [Related]
40. Congress of Neurological Surgeons systematic review and evidence-based guidelines update on the role of targeted therapies and immunotherapies in the management of progressive glioblastoma.
Winograd E; Germano I; Wen P; Olson JJ; Ormond DR
J Neurooncol; 2022 Jun; 158(2):265-321. PubMed ID: 34694567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
